title: Intravenous immunoglobulin therapy for Miller Fisher syndrome.
abstract: We analyzed clinical recovery of 92 patients with Miller Fisher syndrome who had been treated with IV immunoglobulin (IVIg; n = 28), plasmapheresis (n = 23), and no immune treatment (n = 41). IVIg slightly hastened the amelioration of ophthalmoplegia and ataxia, but the times of the disappearances of those symptoms were similar among three groups. In Miller Fisher syndrome, IVIg and plasmapheresis seem not to have influenced patients' outcomes, presumably because of good natural recovery.
authors.affiliation: Department of Neurology, Graduate School of Medicine, Chiba University, Inohana, Chuo-ku, Chiba, Japan. morim@faculty.chiba-u.jp
authors.forename: Masahiro
authors.initials: M
authors.lastname: Mori
authors.forename: Satoshi
authors.initials: S
authors.lastname: Kuwabara
authors.forename: Toshio
authors.initials: T
authors.lastname: Fukutake
authors.forename: Takamichi
authors.initials: T
authors.lastname: Hattori
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D019846:Miller Fisher Syndrome / Q000188:drug therapy*; D010956:Plasmapheresis / Q000379:methods
chemical_list: D016756:Immunoglobulins, Intravenous